ArticleAnnals of translational medicine2022
Treatment of recurrent iliac branch occlusion after endovascular repair of abdominal aortic aneurysm diagnosed by contrast-enhanced ultrasound combined with computed tomography angiography: a case report.
Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endovascular treatment of abdominal aortic aneurysm (AAA) has been in use for several decades and has become the main treatment for this disease. Iliac branch occlusion (IBO) is a common complication after endovascular treatment. The diagnosis and guidance of contrast-enhanced ultrasound (CEUS) combined with computed tomography angiography (CTA) in the treatment of recurrent IBO after endovascular aneurysm repair (EVAR) are rarely reported. In this case, CEUS gave important hints on the cause of IBO. Case Description: We present a 67-year-old male patient who was diagnosed with AAA in 2020 and underwent endovascular treatment in the same period. There was no family history of AAA. The operation process was successful. The CTA re-examination one month after operation showed that the aneurysm was well isolated without obvious endoleak. However, the patient developed intermittent claudication of both lower limbs after operation, but did not receive relevant diagnosis and treatment. Four months after surgery, the patient's claudication symptoms of the left lower limb were significantly worse than before, and CTA review revealed left IBO. The left ankle brachial index (ABI) was too low to detect the value. A femoral artery thrombectomy was performed and a stent was extended distal to the left iliac stent. The claudication symptoms improved after surgery. Unfortunately, only two months later, the patient developed rest pain in the left lower limb. CTA examination showed that the left iliac branch was occluded again. The problem in the proximal end of the left iliac branch was observed by CEUS before re-operation, which was also confirmed by digital subtraction angiography (DSA) after thrombectomy. The blood flow was significantly improved after the angle of the proximal iliac branch was adjusted by stent placement. The patient did not show claudication symptoms again during follow-up. Through CEUS, we identified the pathogenic causes which could not be reflected in CTA and formulated the correct treatment plan. Conclusions: The risk factors of IBO after EVAR are mostly hidden in the process of the initial operation. CEUS can provide more information about postoperative hemodynamics than CTA. The role of CEUS in postoperative follow-up of endovascular treatment of AAA needs to be further explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.